E
Eupraxia Pharmaceuticals Inc. (EPRX)
NCM – Real Time Price. Currency in USD
7.61
+0.19 (2.56%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
7.61
+0.19 (2.56%)
At close: May 12, 2026, 4:00 PM EDT
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
| Name | Position |
|---|---|
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer & COO |
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director |
| Mr. Alex Therien | Executive VP of R&D |
| Mr. Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Corporate Development Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | f6k_050626.htm |
| 2026-05-05 | 6-K | f6k_050526.htm |
| 2026-05-01 | 6-K | f6k_050126.htm |
| 2026-04-22 | 6-K | f6k_042126.htm |
| 2026-04-21 | 6-K | f6k_042126.htm |
| 2026-04-15 | 6-K | f6k_041426.htm |
| 2026-03-17 | 6-K | f6k_031726.htm |
| 2026-03-13 | 40-F | d78249d40f.htm |
| 2026-02-20 | SUPPL | d100065dsuppl.htm |
| 2026-02-20 | 6-K | d219539d6k.htm |